194 related articles for article (PubMed ID: 33882846)
1. Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept.
Lin D; Klein A; Cella D; Beutler A; Fang F; Magestro M; Cremer P; LeWinter MM; Luis SA; Abbate A; Ertel A; Litcher-Kelly L; Klooster B; Paolini JF
BMC Cardiovasc Disord; 2021 Apr; 21(1):201. PubMed ID: 33882846
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial.
Klein AL; Lin D; Cremer PC; Nasir S; Luis SA; Abbate A; Ertel A; LeWinter M; Beutler A; Fang F; Paolini JF
Heart; 2020 Nov; 107(6):488-96. PubMed ID: 33229362
[TBL] [Abstract][Full Text] [Related]
3. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis.
Klein AL; Imazio M; Brucato A; Cremer P; LeWinter M; Abbate A; Lin D; Martini A; Beutler A; Chang S; Fang F; Gervais A; Perrin R; Paolini JF
Am Heart J; 2020 Oct; 228():81-90. PubMed ID: 32866928
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY.
Brucato A; Lim-Watson MZ; Klein A; Imazio M; Cella D; Cremer P; LeWinter MM; Luis SA; Lin D; Lotan D; Pancrazi M; Trotta L; Klooster B; Litcher-Kelly L; Zou L; Magestro M; Wheeler A; Paolini JF;
J Am Heart Assoc; 2022 Oct; 11(20):e023252. PubMed ID: 36250662
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Klein AL; Imazio M; Cremer P; Brucato A; Abbate A; Fang F; Insalaco A; LeWinter M; Lewis BS; Lin D; Luis SA; Nicholls SJ; Pano A; Wheeler A; Paolini JF;
N Engl J Med; 2021 Jan; 384(1):31-41. PubMed ID: 33200890
[TBL] [Abstract][Full Text] [Related]
6. Burden of Recurrent Pericarditis on Health-Related Quality of Life.
LeWinter M; Kontzias A; Lin D; Cella D; DerSarkissian M; Zhou M; Duh MS; Lim-Watson M; Magestro M
Am J Cardiol; 2021 Feb; 141():113-119. PubMed ID: 33220316
[TBL] [Abstract][Full Text] [Related]
7. Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.
Schwier NC
Ann Pharmacother; 2022 May; 56(5):572-581. PubMed ID: 34459270
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives.
Thomas GK; Bonaventura A; Vecchié A; van Tassell B; Imazio M; Klein A; Luis SA; Abbate A
J Cardiovasc Pharmacol; 2024 Jun; 83(6):503-510. PubMed ID: 37163222
[TBL] [Abstract][Full Text] [Related]
9. Rilonacept for the treatment of recurrent pericarditis.
Fava AM; Reyaldeen R; Lo Presti S; Goyal A; Akintoye E; Hughes D; Klein AL
Expert Opin Biol Ther; 2022 Jan; 22(1):7-16. PubMed ID: 34757872
[TBL] [Abstract][Full Text] [Related]
10. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.
Brucato A; Wheeler A; Luis SA; Abbate A; Cremer PC; Zou L; Insalaco A; Lewinter M; Lewis BS; Lin D; Nicholls S; Pancrazi M; Klein AL; Imazio M; Paolini JF
Heart; 2023 Jan; 109(4):297-304. PubMed ID: 36316102
[TBL] [Abstract][Full Text] [Related]
11. Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.
Imazio M; Klein AL; Brucato A; Abbate A; Arad M; Cremer PC; Insalaco A; LeWinter MM; Lewis BS; Lin D; Luis SA; Nicholls SJ; Sutej P; Wasserstrum Y; Clair J; Agarwal I; Wang S; Paolini JF;
J Am Heart Assoc; 2024 Mar; 13(6):e032516. PubMed ID: 38471825
[TBL] [Abstract][Full Text] [Related]
12. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.
Goldbach-Mansky R; Shroff SD; Wilson M; Snyder C; Plehn S; Barham B; Pham TH; Pucino F; Wesley RA; Papadopoulos JH; Weinstein SP; Mellis SJ; Kastner DL
Arthritis Rheum; 2008 Aug; 58(8):2432-42. PubMed ID: 18668591
[TBL] [Abstract][Full Text] [Related]
13. The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever.
Hashkes PJ; Spalding SJ; Hajj-Ali R; Giannini EH; Johnson A; Barron KS; Weisman MH; Pashinian N; Reiff AO; Samuels J; Wright D; Lovell DJ; Huang B
Biomed Res Int; 2014; 2014():854842. PubMed ID: 25147819
[TBL] [Abstract][Full Text] [Related]
14. A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option.
Gupta M; Kaul S; Velazquez GR; Bandyopadhyay D; Fonarow GC; Klein A; Ghosh RK
Am J Cardiovasc Drugs; 2022 Jan; 22(1):27-33. PubMed ID: 34008144
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
Hoffman HM; Throne ML; Amar NJ; Cartwright RC; Kivitz AJ; Soo Y; Weinstein SP
Clin Ther; 2012 Oct; 34(10):2091-103. PubMed ID: 23031624
[TBL] [Abstract][Full Text] [Related]
16. Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis.
Wang TKM; Klein AL
Curr Cardiol Rep; 2022 Jan; 24(1):23-30. PubMed ID: 34993745
[TBL] [Abstract][Full Text] [Related]
17. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
Mantero JC; Kishore N; Ziemek J; Stifano G; Zammitti C; Khanna D; Gordon JK; Spiera R; Zhang Y; Simms RW; Lafyatis R
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):146-149. PubMed ID: 30277862
[TBL] [Abstract][Full Text] [Related]
18. Psychometric properties and general population reference values for PROMIS Global Health in Hungary.
Bató A; Brodszky V; Mitev AZ; Jenei B; Rencz F
Eur J Health Econ; 2024 Jun; 25(4):549-562. PubMed ID: 37378690
[TBL] [Abstract][Full Text] [Related]
19. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.
Terkeltaub RA; Schumacher HR; Carter JD; Baraf HS; Evans RR; Wang J; King-Davis S; Weinstein SP
Arthritis Res Ther; 2013 Feb; 15(1):R25. PubMed ID: 23375025
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.
Hoffman HM; Throne ML; Amar NJ; Sebai M; Kivitz AJ; Kavanaugh A; Weinstein SP; Belomestnov P; Yancopoulos GD; Stahl N; Mellis SJ
Arthritis Rheum; 2008 Aug; 58(8):2443-52. PubMed ID: 18668535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
